How many drugs treat Exacerbation of asthma?

Drug Landscape tracks 9 marketed treatments for Exacerbation of asthma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Exacerbation of asthma?

Most recent: Bupivacaine Hydrochloride And Epinephrine — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/exacerbation-of-asthma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Exacerbation of asthma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exacerbation of asthma (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Exacerbation of asthma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Medrol	methylprednisolone	Generic (originally Upjohn/Pfizer)	Glucocorticoid (corticosteroid)	Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor	1957-10-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Deltasone	prednisone	Generic (originally Schering)	Corticosteroid [EPC]	Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor	1955-01-01
Bupivacaine Hydrochloride And Epinephrine	Epinephrine	Pfizer Inc.	alpha-Adrenergic Agonist [EPC]	Alpha-1D adrenergic receptor	1948-01-01
prednison	prednison	Wen Zhang		Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor
Epinephrin	Epinephrin	United States Naval Medical Center, San Diego		Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor
prednisolon	prednisolon	Hannover Medical School		Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1
Methylprednisolon	Methylprednisolon	Leiden University Medical Center		Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-30 — Bupivacaine Hydrochloride And Epinephrine · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Generic (originally Schering) · 2 drugs in Exacerbation of asthma
Pfizer Inc. · 2 drugs in Exacerbation of asthma
Hannover Medical School · 1 drug in Exacerbation of asthma
Leiden University Medical Center · 1 drug in Exacerbation of asthma
United States Naval Medical Center, San Diego · 1 drug in Exacerbation of asthma
Generic (originally Merck) · 1 drug in Exacerbation of asthma
Wen Zhang · 1 drug in Exacerbation of asthma
Generic (originally Upjohn/Pfizer) · 1 drug in Exacerbation of asthma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Exacerbation of asthma:

Cite this brief

Drug Landscape (2026). Exacerbation of asthma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/exacerbation-of-asthma. Accessed 2026-06-10.

Exacerbation of asthma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing